No Data
Revance to Participate in Upcoming Investor Conferences
Revance Therapeutics, Inc. (NASDAQ:RVNC) today announced that the company will be participating in the following investor conferences. William Blair 44th Annual Growth Stock Conference Chief Financial Officer Tobin
Revance Therapeutics Price Target Cut to $11.00/Share From $12.00 by HC Wainwright & Co.
Revance Therapeutics Price Target Cut to $11.00/Share From $12.00 by HC Wainwright & Co.
HC Wainwright & Co. : Revance Therapeutics (RVNC.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $11.00.
HC Wainwright & Co. : Revance Therapeutics (RVNC.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $11.00.
Revance Therapeutics Is Maintained at Neutral by Goldman Sachs
Revance Therapeutics Is Maintained at Neutral by Goldman Sachs
Goldman Sachs Maintains Neutral on Revance Therapeutics, Lowers Price Target to $8
Goldman Sachs analyst Chris Shibutani maintains Revance Therapeutics with a Neutral and lowers the price target from $9 to $8.
Barclays Sticks to Its Buy Rating for Revance Therapeutics (RVNC)